Leukemia research highlights from ASCO 2023
Click Here to Manage Email Alerts
This year’s ASCO Annual Meeting included essential research updates across the field.
Healio compiled a list of interesting and important studies in leukemia presented at the meeting, including studies assessing new treatment options, investigating disparities in care in certain patient populations and more.
1. Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed. Read more.
2. Fewer than half of adolescents and young adults with acute lymphoblastic leukemia received first-line treatment at a specialized cancer center, despite an association of such treatment with longer survival, study results showed. Read more.
3. The addition of venetoclax (Venclexta; Genentech, AbbVie) to ibrutinib (Imbruvica; Pharmacyclics, Janssen) and obinutuzumab (Gazyva, Genentech) did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting. Read more.
4. A partnership between health care systems along the U.S.-Mexico border led to clinically meaningful improvement in survival outcomes among children with acute lymphoblastic leukemia, study results showed. Read more.
5. Seventy-six percent of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel (AUTO1; Autolus Therapeutics), interim results of the pivotal phase 2 FELIX trial showed. Read more.
6. Higher tumor mutational burden appeared associated with more favorable real-world OS among a large cohort of patients with various cancer types who used immune checkpoint inhibitor monotherapy. Read more.
7. Ivosidenib (Tibsovo, Servier) extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial. Read more.
Collapse
Healio Listicle
Click Here to Manage Email Alerts